Abiopharma

🔍 Maduck Sean (Executive)

Company: CORCEPT THERAPEUTICS INC (CORT)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 30,955 shares of Common Stock at $11.35 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: false | shares_owned_after: 40,710.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 25,085 shares of Common Stock at $125.4676 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 15,625.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
• Sold 5,870 shares of Common Stock at $126.0588 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 9,755.00 | transaction_form_type: 4 | Footnotes: F2, F4, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 5,147.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 20,570.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 40,000.00 | Footnotes: F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 34,000.00 | Footnotes: F8
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 10,000.00 | Footnotes: F9
• Sold 30,955 shares of Stock option (right to buy) at $11.35 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2029-02-08 | equity_swap_involved: false | shares_owned_after: 169,045.00 | transaction_form_type: 4 | Footnotes: F10

Footnotes:

• F1: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
• F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
• F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F5: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
• F6: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
• F7: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
• F8: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
• F9: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
• F10: Fully exercisable.
• REMARKS: President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.